Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Rheumatology (Oxford). 2019 Jun 1;58(6):1034-1039. doi: 10.1093/rheumatology/key420.
To identify biomarkers for assessing myositis-associated interstitial lung disease (ILD).
We reviewed consecutive patients from our institution who had been newly diagnosed with PM, DM, or clinically amyopathic DM during the years 2002-2017. The patients were divided into two groups according to the presence of ILD, and the ILD group was further subdivided into three groups according to the clinical courses of induction failure, relapse and non-relapse. Baseline and time-course changes in the parameters were compared between groups.
Among 110 patients enrolled, 75 (68%) had ILD. Baseline serum Krebs von den Lungen-6 (KL-6) was significantly higher in the ILD group than in the non-ILD group (1120 vs 236 U/ml; P < 0.001). In the ILD group consisting of the induction failure cases (n = 3), the relapse group (n = 24) and the non-relapse group (n = 48), baseline serum KL-6 was significantly different between the three groups [1971 vs 1870 vs 935 U/ml, respectively; P = 0.003 (relapse group vs non-relapse group)]. The time-course changes in serum KL-6 revealed that KL-6 significantly increased along with relapse, with the increase of 625 U/ml relevant to relapse.
Serum KL-6 is a useful biomarker for assessing the disease activity of myositis-associated ILD.
寻找评估肌炎相关性间质性肺病（ILD）的生物标志物。
我们回顾了 2002 年至 2017 年期间我院新诊断为皮肌炎、多发性肌炎或临床无肌病性皮肌炎的连续患者。根据是否存在ILD，将患者分为两组，ILD 组根据诱导失败、复发和非复发的临床病程进一步分为三组。比较各组间基线和时间过程中参数的变化。
在纳入的 110 例患者中，75 例（68%）有ILD。ILD 组的基线血清 Krebs von den Lungen-6（KL-6）明显高于非ILD 组（1120 比 236 U/ml；P < 0.001）。在包括诱导失败病例（n = 3）、复发组（n = 24）和非复发组（n = 48）的ILD 组中，三组间基线血清 KL-6 差异显著[分别为 1971、1870 和 935 U/ml；P = 0.003（复发组与非复发组）]。血清 KL-6 的时间过程变化表明，随着复发，KL-6 显著增加，与复发相关的增加 625 U/ml。
血清 KL-6 是评估肌炎相关性ILD 疾病活动的有用生物标志物。
